GLPwatch

Semaglutide for the treatment of obesity.

Trends Cardiovasc Med · 2023

Last updated 2026-05-28

Semaglutide, a once-weekly injectable medication, was approved for long-term weight management. In a 68-week study, people taking a 2.4 mg dose lost about 15% of their starting body weight on average, and also showed improvements in factors like blood sugar control and heart health risks.

AI summary of the abstract below.

JournalTrends Cardiovasc Med, 2023
Citations138
Relative citation ratio19.89
NIH percentile99
Molecules semaglutide
Conditions studied Obesity

Abstract

Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. This paper reviews data on the mechanism of action, weight-loss and cardiometabolic efficacy, and safety of semaglutide 2.4 mg/week for obesity. Semaglutide has demonstrated the largest weight loss of any obesity medication to date with reductions of approximately 15% of initial weight at 68 weeks, accompanied by improvements in cardiovascular risks factors and physical functioning. The approval of this medication provides patients with greater options for weight management.

Verbatim abstract via PubMed 34942372 ↗

Related research